Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model
Blood Cancer Journal, Published online: 19 July 2023; doi:10.1038/s41408-023-00869-9Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 19, 2023 Category: Hematology Authors: Kotaro Shide Katsuto Takenaka Akira Kitanaka Akihiko Numata Takuro Kameda Takuji Yamauchi Atsushi Inagaki Shohei Mizuno Akiyoshi Takami Shinichi Ito Masao Hagihara Kensuke Usuki Takaaki Maekawa Kazutaka Sunami Yasunori Ueda Miyuki Tsutsui Miki Ando Norio Source Type: research
Global disparities in patients with multiple myeloma: a rapid evidence assessment
Blood Cancer Journal, Published online: 18 July 2023; doi:10.1038/s41408-023-00877-9Global disparities in patients with multiple myeloma: a rapid evidence assessment (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 18, 2023 Category: Hematology Authors: Maria-Victoria Mateos Sikander Ailawadhi Luciano J. Costa Shakira J. Grant Lalit Kumar Mohamad Mohty Didem Aydin Saad Z. Usmani Source Type: research
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
Blood Cancer Journal, Published online: 18 July 2023; doi:10.1038/s41408-023-00878-8Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 18, 2023 Category: Hematology Authors: Ayalew Tefferi Hassan Alkhateeb Naseema Gangat Source Type: research
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia
Blood Cancer Journal, Published online: 12 July 2023; doi:10.1038/s41408-023-00881-zDonor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 12, 2023 Category: Hematology Authors: Ibrahim Aldoss Samer K. Khaled Yan Wang Xiuli Wang Joycelynne Palmer Mary C. Clark Jamie R. Wagner Jinny Paul Vibhuti Vyas Christine E. Brown Stephen J. Forman Source Type: research
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms
Blood Cancer Journal, Published online: 10 July 2023; doi:10.1038/s41408-023-00875-xTargeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 10, 2023 Category: Hematology Authors: Charly Courdy Lo ïc Platteeuw Charlotte Ducau Isabelle De Araujo Emeline Boet Ambrine Sahal Estelle Saland Val érie Edmond Suzanne Tavitian Sarah Bertoli Pierre Cougoul Fanny Granat Laura Poillet Caroline Marty Isabelle Plo Jean-Emmanuel Sarry St éphan Source Type: research
Potential value of pre-planned imaging of bone disease in multiple myeloma
Blood Cancer Journal, Published online: 07 July 2023; doi:10.1038/s41408-023-00880-0Potential value of pre-planned imaging of bone disease in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 7, 2023 Category: Hematology Authors: Michael T. Gundesen Jon Thor Asmussen Fredrik Schjesvold Annette Juul Vangsted Carsten Helleberg Einar Hauk ås Trine Silkj ær Elena Manuela Teodorescu Bo Amdi Jensen Tobias S. Sl ørdahl Hareth Nahi Anders Waage Niels Abildgaard Thomas Lund Source Type: research
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
Blood Cancer Journal, Published online: 06 July 2023; doi:10.1038/s41408-023-00862-2Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 6, 2023 Category: Hematology Authors: Franck Rapaport Kenneth Seier Yaseswini Neelamraju Duane Hassane Timour Baslan Daniel T. Gildea Samuel Haddox Tak Lee H. Moses Murdock Caroline Sheridan Alexis Thurmond Ling Wang Martin Carroll Larry D. Cripe Hugo Fernandez Christopher E. Mason Elisabeth Source Type: research
Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
Blood Cancer Journal, Published online: 06 July 2023; doi:10.1038/s41408-023-00866-yCorrection: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 6, 2023 Category: Hematology Authors: Noopur Raje Mar ía-Victoria Mateos Shinsuke Iida Donna Reece Source Type: research
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
Blood Cancer Journal, Published online: 04 July 2023; doi:10.1038/s41408-023-00870-2Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 4, 2023 Category: Hematology Authors: P. J. Hengeveld J. Schilperoord-Vermeulen M. Y. van der Klift J. M. N. Dubois P. M. Kolijn F. G. Kavelaars M. Rijken J. A. Dobber K. Nasserinejad S. Kersting P. E. Westerweel A. P. Kater A. W. Langerak M-D. Levin Source Type: research
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
Blood Cancer Journal, Published online: 29 June 2023; doi:10.1038/s41408-023-00871-1A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 29, 2023 Category: Hematology Authors: Jayastu Senapati Muharrem Muftuoglu Jo Ishizawa Hussein A. Abbas Sanam Loghavi Gautam Borthakur Musa Yilmaz Ghayas C. Issa Samuel I. Dara Mahesh Basyal Li Li Kiran Naqvi Rasoul Pourebrahim Elias J. Jabbour Steven M. Kornblau Nicholas J. Short Naveen Pemma Source Type: research
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
Blood Cancer Journal, Published online: 28 June 2023; doi:10.1038/s41408-023-00865-zOutcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 28, 2023 Category: Hematology Authors: Gian Matteo Rigolin Pier Paolo Olimpieri Valentina Summa Simone Celant Lydia Scarf ò Lucia Tognolo Maria Pia Ballardini Antonio Urso Mariarosaria Sessa Silvia Gambara Francesca Cura Monica Fortini Paolo Ghia Antonio Cuneo Pierluigi Russo Source Type: research
Cost comparison of post-remission strategies in younger and older AML patients in France
Blood Cancer Journal, Published online: 28 June 2023; doi:10.1038/s41408-023-00874-yCost comparison of post-remission strategies in younger and older AML patients in France (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 28, 2023 Category: Hematology Authors: Michael Mounie Pierre-Yves Dumas Sandra Liva-Yonnet Didier Fabre Thibault Leguay Jean Galtier Emilie Berard Ramaroson Hanta V éronique Gilleron Sarah Bertoli Arnaud Pigneux Christian R écher Nad ège Costa Source Type: research
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation
Blood Cancer Journal, Published online: 26 June 2023; doi:10.1038/s41408-023-00868-wReal-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 26, 2023 Category: Hematology Authors: Dong Won Baek Joon Ho Moon Jae Hoon Lee Ka-Won Kang Ho Sup Lee Hyeon-Seok Eom Enuyoung Lee Ji Hyun Lee Jeong-Ok Lee Seong Kyu Park Seok Jin Kim Keon Hee Yoo Sung-Soo Yoon Youngil Koh Hyoung Jin Kang Jong-Ho Won Chuhl Joo Lyu Seung Min Hahn Jung-Hee Lee Jo Source Type: research
The DNA methylation status of the TERT promoter differs between subtypes of mature B-cell lymphomas
Blood Cancer Journal, Published online: 26 June 2023; doi:10.1038/s41408-023-00872-0The DNA methylation status of the TERT promoter differs between subtypes of mature B-cell lymphomas (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 26, 2023 Category: Hematology Authors: Alexandra G. Kouroukli Anja Fischer Helene Kretzmer Emil Chteinberg Nivethika Rajaram Selina Glaser Julia Kolarova Pavel Bashtrykov Stephan Mathas Hans G. Drexler Hitoshi Ohno Ole Ammerpohl Albert Jeltsch Reiner Siebert Susanne Bens Source Type: research
Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
Blood Cancer Journal, Published online: 26 June 2023; doi:10.1038/s41408-023-00867-xMonitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 26, 2023 Category: Hematology Authors: Jong-Mi Lee Ari Ahn Eun Jeong Min Sung-Eun Lee Myungshin Kim Yonggoo Kim Source Type: research
